By Fineline Cube 
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a licensing agreement with Lenis, a Slovenian-based full-service regional distributor of niche and specialty Rx medicines, for its Ryzneuta (efbemalenograstim alfa, F-627). Under the agreement, Lenis will be responsible for market planning and sales of the drug in Croatia, Slovenia, Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia, and Serbia, with option rights in the Czech Republic, Slovakia, Bulgaria, and Hungary.
Agreement Details
Yifan Pharma will generate international revenue by selling the product to Lenis, in addition to receiving upfront and milestone payments. Lenis will handle pricing, reimbursement, marketing, distribution, and other related matters for the product. Yifan Pharma will supply the product and provide necessary training and support for related brands.
Ryzneuta Technology and Mechanism
Ryzneuta is a rhG-CSF developed via Yifan’s proprietary Di-Kine bimolecular technology platform. It features long-lasting and potent biological characteristics, primarily functioning as a “leukopoietic agent.” The drug is used to prevent and treat chemotherapy-induced neutropenia in cancer patients, promoting rapid proliferation and recovery of neutrophils. This mechanism enhances the immune system’s ability to combat infections, helping patients avoid complications during chemotherapy treatment.-Fineline Info & Tech